With more than 2,000 clinicians certified in more than 80 medical specialties and subspecialties, UT Physicians provides multispecialty care for the entire family.
There has been an error in displaying this message. Please contact the site administrator.
Nadarajah Vigneswaran, DMD, is a board-certified and fellowship-trained oral and maxillofacial pathologist involved in diagnosing and managing patients with various oral mucosal disorders. He specializes in diagnosing and treating chronic ulcerative and inflammatory diseases of the oral cavity, salivary glands, and jaw bones.
Vigneswaran is a professor in the Department of Diagnostic and Biomedical Sciences at UTHealth Houston School of Dentistry, where he directs the Oral and Maxillofacial Pathology Biopsy Service and is the program director of the school’s oral and maxillofacial pathology residency program. He has a joint appointment at The University of Texas MD Anderson Cancer Center as a clinical professor in the Department of Stem Cell Transplantation and Cellular Therapy. He is a diplomate of the American Board of Oral and Maxillofacial Pathology.
He earned Doctor of Medical Dentistry degrees at Friedrich Alexander University School of Medicine, Erlangen-Nuremberg, and at the University of Alabama School of Dentistry. He completed his oral and maxillofacial pathology residency at Emory University Hospital and his oral pathology and dental oncology fellowship at the University of Alabama at Birmingham.
Vigneswaran is actively involved in clinical and laboratory-based research on oral cancer and its precursors. His clinical research evaluates minimally invasive diagnostic devices for early oral cancer diagnosis and its precursor lesions. His basic research involves the development of experimental animal models for preclinical testing of molecular targeted diagnostic imaging and therapy.
He has more than 175 peer-reviewed scientific publications in high-impact journals and 12 chapters in medical and dental textbooks. He is an invited contributor to the World Health Organization (WHO) Classification of Tumours. He has been an invited presenter for national and international research conferences. He has had continuous grant funding and received over $20 million in grant funding from the National Institutes of Health, the Cancer Prevention and Research Institute of Texas, and UTHealth Houston Center for Translational Sciences/Texas Regional CTSA Consortium as a principal and co-investigator.
All patient experience ratings and comments are submitted by actual patients and are received and validated by a leading independent survey company, NRC Health.
